 "DoP exempts pharmaceutical companies from lowering drug prices based on WPI")
In a relief to the pharmaceutical industry, the Department of Pharmaceuticals has ordered that companies already selling drugs at a price lesser than the ceiling price fixed by the NPPA will not have to revise prices based on the Wholesale Price Index.
The Department of Pharmaceuticals said that the pharma pricing regulator "erred" when it said that even prices of the drugs with Maximum Retail Price below the actual ceiling price fixed by the NPPA should be revised. The Department's order says, "NPPA is therefore directed to revise the Ceiling Price of Schedule I medicines each year in accordance with the WPI revision.
Individual companies/ brands/ medicines which are already having an MRP below or equal to such WPI adjusted Ceiling Price shall not be required to reduce the MRPs any further vis-a-vis the WPI."
Individual companies/ brands/ medicines which are already having an MRP below or equal to such WPI adjusted Ceiling Price shall not be required to reduce the MRPs any further vis-a-vis the WPI."
The Indian Pharmaceutical Alliance argued, "The DPCO 2013 mandates reduction of prices only with reference to the Ceiling Price and not the MRPs."
The Indian Pharmaceutical Alliance, a body of pharmaceutical majors had asked the Department of Pharmaceuticals to consider this move saying that 5000-odd small and medium enterprises will benefit from the move.
According to the old rules, pharmaceutical companies have to revise their prices based on the Wholesale Price Index of the previous year.
According to the old rules, pharmaceutical companies have to revise their prices based on the Wholesale Price Index of the previous year.
This petition was filed by the Indian Pharmaceutical Alliance early last year and was one of pain points for the pharmaceutical industry. This added to the existing tension between the NPPA and the pharmaceutical companies.
Previously, the NPPA insisted that all companies revise their prices as based on the Wholesale Price Index even if their prices are much below the ceiling price fixed by the pharmaceutical pricing authority. The NPPA fixes prices of drugs that are part of the National List of Essential Medicines. Prices of 530 drugs have been fixed by the NPPA.
Previously, the NPPA insisted that all companies revise their prices as based on the Wholesale Price Index even if their prices are much below the ceiling price fixed by the pharmaceutical pricing authority. The NPPA fixes prices of drugs that are part of the National List of Essential Medicines. Prices of 530 drugs have been fixed by the NPPA.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%